MYCN and prostate carcinoma: As with prostate cancer, AURKA has been linked to the disease but its inhibition does not alter MYCN levels, suggesting a difference in activity in MYCN-amplified non-small lung cancer cells (NSCLC) compared to MYCN-amplified neuroblastoma and prostate cancer [184].